Korean J Perinatol.  2013 Dec;24(4):221-228. 10.14734/kjp.2013.24.4.221.

Intestinal Microbiota in Preterm Infants and Probiotics Use for Disease Prevention

• Kim ES

• KMID: 2072297
• DOI: http://doi.org/10.14734/kjp.2013.24.4.221

Abstract

Infectious complications such as necrotizing enterocolitis (NEC) or neonatal sepsis are main causes of mortality and disability in very low birth weight infants (VLBWIs). Because preterm infants are exposed to too unfavorable environment to promote appropriate intestinal colonization, pathologic organisms can easily colonize and host defense systems are also down-regulated in preterm gut, causing infectious complications such as NEC. To promote appropriate intestinal microbiota, probiotics have been studied for potential benefits by increasing mucosal barrier function, reducing intestinal pathogens, up-regulating immune system balancing inflammation. Large randomized controlled trials have shown favorable effects of probiotics on preterm NEC and mortality. Meta-analysis of clinical trials showed consistent evidence of probiotics uses in preterm infants. However, adequate type, dose, timing, and duration of probiotics have not been standardized for clinical applications. In addition, other interventions promoting preterm intestinal micobiota and immunity, such as prebiotics or lactoferrin, are on studies in combination with probiotics. More clinical trials should be added for the evidence-based clinical use of probiotics in preterm infants.

Keyword

Probiotics; Preterm infants; Necrotizing enterocolitis; Mortality

MeSH Terms

Colon
Enterocolitis, Necrotizing
Humans
Immune System
Infant
Infant, Newborn
Infant, Premature*
Infant, Very Low Birth Weight
Inflammation
Lactoferrin
Microbiota*
Mortality
Prebiotics
Probiotics*
Sepsis
Lactoferrin
Prebiotics